Free Newsletter
Vendors jockey for bioprocess position
Pall Corp has unveiled the PallSep Biotech system for separating target molecules from process fluids via vibrating membrane filtration technology. Encapsulated hydrophilic polyethersulfone membrane filter modules provide for "gentle" separation, according to an announcement. The system is intended for use in therapeutic-vaccine and antigen-extract processes.
Pall has also recently launched a 5-milliliter phase reaction conversion (PRC) prepacked chromatography column for protein purification processing. The scalable columns support ion exchange and mixed-mode chromatography to aid in processing consistency. They are available in various separation media for such applications as native and recombinant proteins, plasmids, vaccines, monoclonal and polyclonal antibodies, and plasma derivatives.
Separately, Sartorius Stedim Biotech and Corning announced late last month a collaboration that builds on the companies' existing relationship. The pair will co-market cell culture products through a combined product catalogue and work together on marketing and sales.
- see the PallSep system and PRC column announcements
- here's the Sartorius/Corning announcement
Related Article:
Deal yields single-use fluid-management solutions
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: